The Use of Oral Analgesics and Pain Self-Efficacy Are Independent Predictors of the Quality of Life of Individuals with Rheumatoid Arthritis
Table 3
Independent t-tests between EQ-5D-5L and studied variables.
Parameters
Number of patients n (%)
EQ-5D-5L
P value
Mean
Median
Standard deviation
Range
Sex
0.183
Female
74 (87.1)
0.8008
0.8406
0.1595
0.1722–0.9384
Male
11 (12.9)
0.8686
0.9384
0.1303
0.5960–0.9384
RA-related operations
0.055
Absence
45 (52.9)
0.8403
0.8973
0.1205
0.4168–0.9384
Presence
40 (47.1)
0.7750
0.8365
0.1854
0.1722–0.9384
Use of MTX
0.175
Absence
30 (35.3)
0.7782
0.8324
0.1666
0.2466–0.9384
Presence
55 (64.7)
0.8267
0.8973
0.1503
0.1722–0.9384
Use of bDMARDs
0.261
Absence
46 (54.1)
0.8305
0.8406
0.1267
0.4168–0.9384
Presence
39 (45.9)
0.7919
0.8555
0.1782
0.1722–0.9384
Use of oral steroids
0.032
Absence
76 (89.4)
0.8299
0.8893
0.1358
0.1722–0.9384
Presence
9 (10.6)
0.6383
0.7026
0.2213
0.2466–0.9384
Use of oral analgesics
0.001
Absence
60 (70.6)
0.8456
0.8973
0.1235
0.4168–0.9384
Presence
25 (29.4)
0.7233
0.7752
0.1944
0.1722–0.9384
EQ-5D-5L: the European Quality of Life questionnaire, five dimensions, five levels, RA: rheumatoid arthritis, MTX: methotrexate, bDMARDs: biological disease-modifying antirheumatic drugs.
